Lynparza (olaparib) vs Nerlynx (neratinib)
Lynparza (olaparib) vs Nerlynx (neratinib)
Lynparza (olaparib) and Nerlynx (neratinib) are both oral medications used in the treatment of certain types of cancer, but they have different mechanisms of action and are approved for different indications. Lynparza is a PARP inhibitor used primarily for the treatment of BRCA-mutated ovarian, breast, pancreatic, and prostate cancers, and it works by preventing cancer cells from repairing their DNA, leading to cell death. Nerlynx, on the other hand, is a tyrosine kinase inhibitor specifically used to treat HER2-positive breast cancer by blocking signals that promote the growth of cancer cells. Patients should consult with their healthcare provider to determine which medication is appropriate for their specific cancer type and genetic profile.
Difference between Lynparza and Nerlynx
Metric | Lynparza (olaparib) | Nerlynx (neratinib) |
---|---|---|
Generic name | Olaparib | Neratinib |
Indications | Ovarian, breast, pancreatic, and prostate cancers | Early-stage breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase inhibitor | Tyrosine kinase inhibitor |
Brand names | Lynparza | Nerlynx |
Administrative route | Oral | Oral |
Side effects | Anemia, nausea, fatigue, vomiting, etc. | Diarrhea, nausea, abdominal pain, fatigue, etc. |
Contraindications | Known hypersensitivity to olaparib | Known hypersensitivity to neratinib or any of its excipients |
Drug class | PARP inhibitor | TKI (tyrosine kinase inhibitor) |
Manufacturer | AstraZeneca and Merck & Co. (MSD) | Puma Biotechnology |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy known as a PARP inhibitor, which is used in the treatment of certain types of breast cancer. Specifically, it is indicated for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously received chemotherapy. The efficacy of Lynparza in breast cancer was demonstrated in clinical trials, such as the OlympiAD trial, which showed a significant improvement in progression-free survival (PFS) in patients treated with olaparib compared to those who received standard chemotherapy. Patients treated with Lynparza had a median PFS of 7.0 months compared to 4.2 months for those on chemotherapy, indicating a substantial delay in disease progression.
In addition to improving PFS, Lynparza has also been associated with a higher response rate compared to chemotherapy. In the same OlympiAD trial, the objective response rate (ORR) for patients treated with Lynparza was 52%, compared to 23% for those receiving chemotherapy. This suggests that Lynparza can lead to a significant reduction in tumor size in a higher proportion of patients.
Nerlynx (Neratinib) Efficacy in Breast Cancer
Nerlynx, or neratinib, is a tyrosine kinase inhibitor specifically designed to target HER2-positive breast cancer. It is approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. The ExteNET study, a pivotal phase III clinical trial, showcased the efficacy of neratinib in this setting. Patients taking Nerlynx after completing one year of trastuzumab therapy demonstrated a 2-year invasive disease-free survival (iDFS) rate of 94.2%, compared to 91.9% for those on placebo, indicating a reduction in the risk of disease recurrence.
Further analysis of the ExteNET study with extended follow-up demonstrated sustained benefit with Nerlynx, with a continued separation in the iDFS curves between the neratinib and placebo groups. The five-year iDFS rate was 90.2% in the neratinib group compared to 87.7% in the placebo group. This long-term data reinforces the role of Nerlynx in reducing the risk of breast cancer recurrence in patients with early-stage HER2-positive disease who have completed trastuzumab-based adjuvant therapy.
Regulatory Agency Approvals
Lynparza
Nerlynx
Access Lynparza or Nerlynx today
If Lynparza or Nerlynx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us